Merit Medical Systems v. Vascular Access Direct: Inflation Device Patent Suit Dismissed in 32 Days
Merit Medical Systems filed suit in Delaware asserting three patents covering digital inflation device technology against Vascular Access Direct. The case ended in voluntary dismissal without prejudice just 32 days after filing — leaving future enforcement options open and raising questions about what drove the swift exit.
A rapid voluntary exit in a three-patent inflation device dispute
On May 23, 2025, Merit Medical Systems, Inc. filed an infringement action in the Delaware District Court against Vascular Access Direct, LLC, asserting three patents — US7892202B2, US8398588B1, and US8118776B2 — directed at digital inflation device technology. The accused products identified in the complaint were Vascular Access Direct’s Blue Diamond® Digital Inflation Device, DiamondTOUCH™ Digital Inflation Device, and INT® Force Digital Inflation Device. Merit Medical was represented by Dorsey & Whitney LLP; no counsel of record appeared for the defendant.
The case closed on June 24, 2025 — just 32 days after filing — when Merit Medical invoked Federal Rule of Civil Procedure 41(a) to voluntarily dismiss all claims against Vascular Access Direct without prejudice. The dismissal order specifies that each party bears its own costs and fees, meaning no cost-shifting was imposed. A dismissal without prejudice preserves Merit Medical’s right to re-file the same claims against the same defendant at a later date, subject to applicable statutes of limitations.
The brevity of the case — 32 days from filing to closure, with no defendant counsel appearing on the docket — is consistent with several scenarios: early settlement or licensing discussions, a strategic decision to re-file in a different forum, or a voluntary pause pending parallel proceedings. The public record does not disclose whether any agreement was reached between the parties. The absence of defendant counsel and the without-prejudice designation together suggest this resolution should not be read as a definitive outcome on the merits.
Filing to Voluntary dismissal in 32 days
32 days — substantially shorter than the median patent case lifespan in Delaware District Court
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a) voluntary dismissal — no merits adjudicated
Federal Rule of Civil Procedure 41(a) permits a plaintiff to voluntarily dismiss an action without a court order early in proceedings. Here, Merit Medical exercised that right before any substantive rulings were entered. Critically, no finding was made on infringement, validity, or enforceability of the three asserted patents — the slate is legally clean for both parties.
No merits rulingWithout prejudice: re-filing remains possible, but the record is silent on terms
The dismissal is expressly without prejudice, meaning Merit Medical retains the right to assert the same three patents against Vascular Access Direct in future proceedings. A ‘with prejudice’ dismissal would have barred re-filing — that outcome did not occur here. However, the public docket does not disclose whether the parties reached any private agreement, license, or covenant not to sue. The absence of that information is significant and should not be interpreted either way.
Re-filing permittedMerit Medical preserves its enforcement position
By dismissing without prejudice, Merit Medical keeps all three patents in an enforceable posture. No adverse ruling on claim construction, infringement, or invalidity was entered. Merit Medical incurs its own legal costs but retains full strategic flexibility — including the ability to re-file, pursue licensing, or shift to an ITC action targeting importation of the accused devices.
Enforcement options intactVascular Access Direct faces continued patent risk
Vascular Access Direct achieved dismissal of this action — but the without-prejudice designation means it cannot treat this as a final resolution. The three asserted patents remain valid and enforceable on their face. Without a license, covenant not to sue, or successful invalidity challenge, the accused product lines — Blue Diamond®, DiamondTOUCH™, and INT® Force digital inflation devices — remain at risk of future suit. Competitors in the digital inflation device space should monitor re-filing activity closely.
Re-filing risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Merit Medical Systems, Inc. | Company | Medical device company — holder of US7892202B2, US8398588B1, and US8118776B2Search in Eureka ↗ |
| Defendant | Vascular Access Direct, LLC | Company | Vascular access medical device company accused of infringing digital inflation device patentsSearch in Eureka ↗ |
| Plaintiff counsel | Alessandra Glorioso | Attorney | Counsel for Merit Medical Systems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Elliot Hales | Attorney | Counsel for Merit Medical Systems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Eric L. Schnabel | Attorney | Counsel for Merit Medical Systems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark A. Miller | Attorney | Counsel for Merit Medical Systems, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Dorsey & Whitney, LLP | Law Firm | Representing Merit Medical Systems, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verbatim dismissal order invokes Fed. R. Civ. P. 41 and makes two dispositive designations: the dismissal is ‘without prejudice,’ preserving Merit Medical’s right to re-file, and cost-bearing is symmetric, with each party absorbing its own fees. No merits determination — on infringement, validity, or claim construction — was entered. The absence of a ‘with prejudice’ qualifier is commercially significant: Vascular Access Direct cannot invoke res judicata or claim preclusion based on this dismissal.
US7892202B2, US8398588B1 & US8118776B2 — Digital Inflation Device Technology
The three asserted patents — US7892202B2, US8398588B1, and US8118776B2 — cover digital inflation device technology used in vascular access and interventional cardiology procedures. Inflation devices are used to inflate and deflate balloons on catheters during angioplasty, stenting, and related procedures; digital variants provide precise pressure measurement and control. The application dates span Merit Medical’s development program in this area, with US7892202B2 originating from application 12/118442, US8398588B1 from 13/399712, and US8118776B2 from 12/638631.
Merit Medical is a major OEM supplier of interventional and vascular access disposables, and this patent portfolio appears designed to protect its premium digital inflation product line against lower-cost competitors. The accused products — Blue Diamond®, DiamondTOUCH™, and INT® Force — are directly competitive offerings targeting the same clinical use case. For device manufacturers and distributors in the interventional cardiology and vascular access space, these three patents represent a material freedom-to-operate risk, particularly for companies developing or sourcing digital inflation devices with similar pressure-sensing and control architectures.
Should you run an FTO against US7892202B2, US8398588B1, and US8118776B2?
Any company designing, manufacturing, importing, or distributing digital inflation devices for interventional or vascular access procedures should treat these three Merit Medical patents as live risks. The without-prejudice dismissal means enforcement has not ended — and the breadth of the three-patent assertion suggests Merit Medical intends to protect this product category aggressively. OEM suppliers, private-label distributors, and catheter lab equipment procurement teams should all conduct or update FTO analyses before launch or continued sale of competing products.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the independent claims of US7892202B2, US8398588B1, and US8118776B2 simultaneously, identify prosecution history estoppel constraints, surface prior art that may support design-around strategies, and flag related continuation or divisional applications in the Merit Medical portfolio. For legal teams preparing an opinion letter or monitoring re-filing activity on this docket, Eureka provides real-time citation and litigation tracking across all three patent families.
Run a freedom-to-operate analysis on US7892202B2 to assess your product’s exposure
Run FTO in Eureka →Similar digital inflation device patent cases in U.S. District Courts
Explore related patent infringement actions involving digital inflation device and vascular access technology filed in Delaware and other U.S. district courts.
What this case signals for the digital inflation device IP landscape
A 32-day voluntary dismissal without prejudice in Delaware rarely marks the end of enforcement — it often marks a reset.
Without prejudice exits are often preludes, not endings
When a plaintiff with three issued patents dismisses 32 days after filing with no defendant counsel on record, the most plausible reading is that the parties began private discussions almost immediately. Monitor for a re-filing, an ITC Section 337 complaint, or a licensing announcement involving these three patents and the accused product lines.
Delaware remains a forum of choice for medical device patent disputes
Merit Medical’s selection of the Delaware District Court — before Judge Gregory B. Williams — is consistent with the forum’s established reputation for efficiently handling complex patent infringement cases. IP teams in the vascular access and interventional device space should maintain freedom-to-operate analyses current for the Delaware docket.
Merit v Vascular — key questions answered
Merit Medical asserted three patents: US7892202B2, US8398588B1, and US8118776B2. All three cover digital inflation device technology used in vascular access and interventional procedures. The accused products were Vascular Access Direct’s Blue Diamond®, DiamondTOUCH™, and INT® Force Digital Inflation Devices.
The case was voluntarily dismissed by Merit Medical under Fed. R. Civ. P. 41(a) just 32 days after filing. No defendant counsel appeared on the docket. The public record does not disclose the reason for the swift dismissal — possibilities include early settlement or licensing discussions, a forum strategy change, or a decision to pursue alternative enforcement routes. No merits ruling was entered.
A dismissal without prejudice means Merit Medical retains the right to re-file the same infringement claims against Vascular Access Direct at a future date, subject to applicable statutes of limitations. It does not constitute a waiver of patent rights, nor does it bar Merit Medical from asserting the same patents against other defendants. No court found the patents invalid or not infringed.
Merit Medical was represented by Dorsey & Whitney LLP, with attorneys Alessandra Glorioso, Elliot Hales, Eric L. Schnabel, and Mark A. Miller appearing on record. No counsel of record appeared on behalf of Vascular Access Direct during the 32-day lifespan of the case.
No. A without-prejudice dismissal provides no preclusive protection. Vascular Access Direct cannot invoke res judicata or claim preclusion based on this dismissal. Merit Medical’s three asserted patents — US7892202B2, US8398588B1, and US8118776B2 — remain valid and enforceable. Vascular Access Direct should consider seeking a freedom-to-operate opinion or a licensing arrangement to mitigate ongoing risk.
PatSnap Eureka searches patents and litigation data to answer instantly.